The targets: Boston Scientific, Johnson & Johnson’s Cordis, Eli Lilly, Cephalon and AstraZeneca. The products at issue: Seroquel, Zyprexa, Fentora, Actiq and drug-coated stents.

U.S. Rep. Henry Waxman, who heads the House Committee on Oversight and Government Reform sent letters last Thursday looking for truckloads of information about clinical trials, industry conferences, correspondence, marketing brochures, and so much more.

Boston Scientific issued a brief statement saying it will cooperate. A Cordis spokesman sent Pharmalot an e-mail saying the company will also cooperate. The committee set a March 21 deadline to provide the documents.

And after the paperwork is gathered, you know that hearings won’t be far behind. Drugmakers will be in the hot seat. Lights, cameras, uncomfortable moments.

[tags]AstraZeneca, Boston Scientific, Cephalon, Cordis, Eli Lilly, Henry Waxman, Johnson & Johnson[/tags]